Tirzepatide and New Zealand: Why UK Residents Should Know the Difference

What the trial data actually showed, and why it matters for UK patients

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes across 72 weeks. Participants on the highest dose of tirzepatide lost an average of around 20–21% of their body weight. That figure put it ahead of any previously licensed weight-loss injection when the trial reported. A later head-to-head comparison in the SURMOUNT-5 trial reinforced the finding: tirzepatide produced greater average weight reduction than semaglutide 2.4mg over the same period.

The mechanism behind those numbers is what makes tirzepatide distinct. It activates two gut-hormone receptors simultaneously (GIP and GLP-1) which together slow gastric emptying, increase feelings of fullness, and influence blood-sugar regulation. No other weight-loss medicine licensed in the UK works on both pathways at once. That dual action is why the clinical results sit higher than those for single-pathway medicines.

For anyone in the UK reading about tirzepatide, these are the figures that are directly relevant. Data from New Zealand trials or Medsafe review processes apply to a different regulatory environment; the NICE appraisal TA1026, which evaluated this evidence for the UK's National Health Service, is the document that governs NHS access here. You can read NICE's full recommendation for tirzepatide on their website.

Tirzepatide's UK licence, and why country of access is not interchangeable

In the UK, tirzepatide (Mounjaro) holds a licence for weight management in adults with a BMI of 30 or above, or 27 or above where at least one weight-related health condition is present. It carries a Black Triangle designation, meaning the MHRA keeps it under additional monitoring as post-market safety data accumulates. That licence was granted by the MHRA, which is the UK regulator, entirely separate from Medsafe in New Zealand or the FDA in the United States.

This matters practically. A prescription written by a New Zealand prescriber cannot be dispensed legally at a UK pharmacy, and a UK prescription has no standing at a New Zealand pharmacy. If you have been on tirzepatide overseas and are now in the UK, or vice versa, the clinical assessment needs to happen in the country where you intend to collect treatment. Transfer patients in the UK will typically be asked for evidence of their current dose and recent treatment history before a prescriber continues the same regimen. Our overview of the difference between Mounjaro and tirzepatide as names clarifies the brand and generic naming that can cause confusion when patients move between countries.

A quick way to confirm any UK online pharmacy's legitimacy takes under a minute: visit the GPhC register at pharmacyregulation.org/registers and search the pharmacy's name. If it is not listed, stop. That single check filters out the majority of unlicensed sellers.

What to expect from UK treatment, eligibility, dosing schedule, and practical realities

UK treatment with tirzepatide starts at 2.5mg. That first pen's job is adjustment: giving the body time to settle before the dose is increased, which is why most people find any initial nausea manageable and transient. From there the prescriber typically steps through 5mg, 7.5mg, and then on to tirzepatide 10mg, a mid-range dose that many patients reach after the earlier adjustment stages, 12.5mg and up to 15mg, spending around four weeks at each level. Exactly how and when to move is a clinical decision, not something to self-determine based on information written for patients in another country. Side effects are predominantly gastrointestinal: nausea, loose stools and occasional vomiting are most common at the start or after a dose step, and they usually settle within a week or two.

Eligibility for private treatment in the UK is set by the medicine's licence and assessed by a prescriber. BMI is one factor; so is medical history, current medicines and a range of other clinical variables. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. For information on how the NHS is rolling out tirzepatide, our tirzepatide overview covers the phased eligibility criteria in detail. People who do not meet NHS thresholds, or who prefer not to wait, can access treatment through a regulated private pharmacy provided a prescriber confirms suitability.

On cost: private tirzepatide in the UK is priced by dose and provider. Following Eli Lilly's list-price revision in September 2025, typical private prices range roughly £149–£375 per month depending on dose and supplier, and patients moving up the schedule may want to read about tirzepatide 30, covering what higher-dose supply involves and how it is priced. For a clear breakdown of what reputable pricing includes, the cost context page for Mounjaro in the UK sets out what headline prices often leave out. The right frame for evaluating cost is not which number is smallest; it is whether the price covers genuine licensed supply, clinical oversight, and the aftercare to use treatment safely.

Accessing tirzepatide through a UK-regulated service

The legal route to tirzepatide in the UK is a prescription issued by a qualified prescriber following an assessment of your health. That assessment cannot be skipped, and no legitimate UK pharmacy will dispense without one. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated decision system. Our pharmacy holds GPhC premises registration 9012878, verifiable directly on the GPhC register.

Treatment is sourced through the licensed UK supply chain, dispatched the same day for orders placed before 12pm on working days, and delivered free the next working day by DPD in plain packaging. Aftercare is available seven days a week. There are no subscriptions; each repeat order receives its own clinical review, and if you want to understand the compounded and alternative formulations sometimes marketed online, our page on tirzepatide l explains what that designation refers to and how it differs from the licensed product. If you are coming to the UK from New Zealand and wish to continue treatment, or you are exploring tirzepatide for the first time, our weight-loss treatment overview is a useful starting point. You are welcome to get in touch with our team with questions before you begin.

When you are ready, you can start your free consultation and have your answers reviewed by one of our prescribers the same day.